The TRAINER phase II study evaluates #Biomarker-driven total #Neoadjuvant therapy with bevacizumab or cetuximab for high-risk #RectalCancer, reporting complete responses and high sphincter preservation.

#STTT #OpenAccess: doi.org/10.1038/s413...

#GAIN-2 #GBG68: More intensive #chemotherapy, better response does not necessarily mean better #survival.

Read the publication: www.nature.com/articles/s41...

#ClinicalTrials #Neoadjuvant #adjuvant #GBG